John Neoptolemos Wilko Weichert Christophe Nemos Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results REFERENCE: National Cancer Re
John Neoptolemos
Wilko Weichert
Christophe Nemos
Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results
REFERENCE: National Cancer Research Institute Upper Gastrointestinal Cancer Group Studies Conference, Royal College of Physicians, London July 6th, 2006
John Neoptolemos, Royal Liverpool University Hospital
Encouraging progress regarding adjuvant chemotherapy for patients with resectable pancreatic cancer was reported at the National Cancer Research Institute Upper Gastrointestinal Cancer Conference in London. Peter Goodwin spoke with John Neoptolemos of Liverpool University about improvements in survival reported by the ESPAC trial of adjuvant chemotherapy, growth-factor directed therapies, gemcitabine, and capecitabine (reported at the conference by Naureen Starling of the Royal Marsden Hospital in Surrey), and news about a new pancreatic cancer vaccine (announced by Gary Middleton from the Royal Surrey Hospital in Guildford).
NFkB Transcription Factor: A Key To Controlling Pancreatic Cancer Progression?
REFERENCE: American Association for Cancer Research 97th Annual Meeting 1st-5th April 2006, Washington, DC. Abstract 414
Wilko Weichert, Charité University Hospital, Berlin
Exciting new insights into the mechanism of pancreatic cancer progression were unveiled at the American Association for Cancer Research Annual Meeting in Washington, DC. Wilko Weichert from the Charité University Hospital in Berlin presented his group’s study looking at the behavior of the gene transcription factor NFkB, which modulates programmed cell death (apoptosis) and consequently the proliferative behavior of the tumor. He told Peter Goodwin how their recent investigation has given hope that this mechanism may be harnessed for therapy that will complement existing drug treatments for patients with pancreatic cancer.
MUC4 mRNA in Human Blood: Prognosis and Diagnosis of Pancreatic Adenocarcinoma
REFERENCE: American Association for Cancer Research 97th Annual Meeting 1st-5th April 2006, Washington, DC. Abstract 415
Christophe Nemos, University of Nebraska Medical Center, Omaha
A new blood test for pancreatic cancer was under discussion at the American Association for Cancer Research Annual Meeting held in Washington, DC. In some patients the results of the test proved to signal pancreatic cancer six months before the disease became detectable by other means. Christophe Némos of the University of Nebraska in Omaha told Peter Goodwin about his group’s use of MUC4 mRNA molecule normally present in tumor tissue, which has now been measured in the blood. The hope is that very early detection of the disease could improve further the rates of survival made possible by early resection combined with chemotherapy.
[audio:https://www.audiomedica.com/podcasting/asco/06.08.01_ASCO_podcast.mp3]